Subscribe To
Imago biosciences presents positive data from ongoing phase 2 study of bomedemstat in essential thrombocythemia at ash 2022
– 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a media...
December 12, 2022, 4:30 pm